Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(14%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
5
71%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(3)

Detailed Status

Completed3
Not yet recruiting2
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

completed343%
enrolling_by_invitation114%
not_yet_recruiting229%
recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
not_yet_recruitingphase_2

The Progressive Supranuclear Palsy Clinical Trial Platform

NCT07173803
recruitingphase_2

Alzheimer's Tau Platform: Master Protocol

NCT06957418
enrolling_by_invitationphase_2

Alzheimer's Tau Platform: Regimen A - AADvac1

NCT07167966
not_yet_recruitingphase_2

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

NCT07217665
completedphase_2

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

NCT02579252
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07173803Phase 2

The Progressive Supranuclear Palsy Clinical Trial Platform

Not Yet Recruiting
NCT06957418Phase 2

Alzheimer's Tau Platform: Master Protocol

Recruiting
NCT07167966Phase 2

Alzheimer's Tau Platform: Regimen A - AADvac1

Enrolling By Invitation
NCT07217665Phase 2

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

Not Yet Recruiting
NCT02579252Phase 2

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

Completed
NCT02031198Phase 1

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

Completed
NCT01850238Phase 1

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7